Gain Therapeutics Inc
GANX2.875USD
+0.625+27.78%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
103.43MMarket Cap
LossP/E TTM
More Details of Gain Therapeutics Inc Company
Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of glucocerebrosidase or GCase, function in the lysosome, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.
Gain Therapeutics Inc Info
Ticker SymbolGANX
Company nameGain Therapeutics Inc
IPO dateMar 18, 2021
CEOMack (Gene)
Number of employees23
Security typeOrdinary Share
Fiscal year-endMar 18
Address4800 Montgomery Lane, Suite 220
CityBETHESDA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code20814
Phone13015001556
Websitehttps://www.gaintherapeutics.com/
Ticker SymbolGANX
IPO dateMar 18, 2021
CEOMack (Gene)
Company Executives of Gain Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Khalid Islam, Ph.D.
Mr. Khalid Islam, Ph.D.
Chairman of the Board, Founder
Chairman of the Board, Founder
930.78K
--
Mr. Hans Peter Hasler
Mr. Hans Peter Hasler
Independent Director
Independent Director
--
--
Mr. Gianluca Fuggetta
Mr. Gianluca Fuggetta
Senior Vice President - Finance, Principal Financial Officer
Senior Vice President - Finance, Principal Financial Officer
--
--
Mr. Gene Mack
Mr. Gene Mack
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Gwen A. Melincoff
Ms. Gwen A. Melincoff
Independent Director
Independent Director
--
--
Dr. Dov A. Goldstein, M.D.
Dr. Dov A. Goldstein, M.D.
Independent Director
Independent Director
--
--
Mr. Jeffrey Riley
Mr. Jeffrey Riley
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Khalid Islam, Ph.D.
Mr. Khalid Islam, Ph.D.
Chairman of the Board, Founder
Chairman of the Board, Founder
930.78K
--
Mr. Hans Peter Hasler
Mr. Hans Peter Hasler
Independent Director
Independent Director
--
--
Mr. Gianluca Fuggetta
Mr. Gianluca Fuggetta
Senior Vice President - Finance, Principal Financial Officer
Senior Vice President - Finance, Principal Financial Officer
--
--
Mr. Gene Mack
Mr. Gene Mack
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Gwen A. Melincoff
Ms. Gwen A. Melincoff
Independent Director
Independent Director
--
--
Dr. Dov A. Goldstein, M.D.
Dr. Dov A. Goldstein, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Islam (Khalid)
2.42%
Edward Jones
1.76%
Greenlight Capital, Inc.
1.47%
The Vanguard Group, Inc.
1.39%
Citadel Advisors LLC
0.97%
Other
91.99%
Shareholders
Shareholders
Proportion
Islam (Khalid)
2.42%
Edward Jones
1.76%
Greenlight Capital, Inc.
1.47%
The Vanguard Group, Inc.
1.39%
Citadel Advisors LLC
0.97%
Other
91.99%
Shareholder Types
Shareholders
Proportion
Investment Advisor
4.00%
Individual Investor
3.40%
Hedge Fund
2.94%
Research Firm
2.23%
Investment Advisor/Hedge Fund
2.00%
Venture Capital
0.14%
Other
85.29%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
63
3.80M
12.80%
--
2025Q3
65
3.80M
12.82%
--
2025Q2
66
3.80M
14.97%
+979.62K
2025Q1
65
2.82M
14.28%
-1.29M
2024Q4
58
1.98M
13.85%
+308.45K
2024Q3
55
1.80M
14.76%
-1.37M
2024Q2
53
3.17M
8.36%
+1.17M
2024Q1
47
2.00M
9.88%
+215.07K
2023Q4
45
1.68M
10.82%
+29.72K
2023Q3
44
1.65M
12.01%
+247.80K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Islam (Khalid)
930.78K
2.59%
--
--
Apr 25, 2025
Edward Jones
676.89K
1.88%
+249.19K
+58.26%
Jun 30, 2025
Greenlight Capital, Inc.
566.13K
1.57%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
534.35K
1.49%
+279.36K
+109.56%
Jun 30, 2025
Citadel Advisors LLC
161.82K
0.45%
+142.80K
+750.81%
Jun 30, 2025
Geode Capital Management, L.L.C.
290.46K
0.81%
+8.25K
+2.92%
Jun 30, 2025
Cambridge Investment Research Advisors, Inc.
179.50K
0.5%
+120.00K
+201.68%
Jun 30, 2025
Richman (Eric I.)
304.46K
0.85%
--
--
Apr 25, 2025
Marshall Wace LLP
276.43K
0.77%
+80.41K
+41.02%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
76.51K
0.21%
-14.00K
-15.47%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Micro-Cap ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Gain Therapeutics Inc?
The top five shareholders of Gain Therapeutics Inc are:
Islam (Khalid) holds 930.78K shares, accounting for 2.59% of the total shares.
Edward Jones holds 676.89K shares, accounting for 1.88% of the total shares.
Greenlight Capital, Inc. holds 566.13K shares, accounting for 1.57% of the total shares.
The Vanguard Group, Inc. holds 534.35K shares, accounting for 1.49% of the total shares.
Citadel Advisors LLC holds 161.82K shares, accounting for 0.45% of the total shares.
Islam (Khalid) holds 930.78K shares, accounting for 2.59% of the total shares.
Edward Jones holds 676.89K shares, accounting for 1.88% of the total shares.
Greenlight Capital, Inc. holds 566.13K shares, accounting for 1.57% of the total shares.
The Vanguard Group, Inc. holds 534.35K shares, accounting for 1.49% of the total shares.
Citadel Advisors LLC holds 161.82K shares, accounting for 0.45% of the total shares.
What are the top three shareholder types of Gain Therapeutics Inc?
The top three shareholder types of Gain Therapeutics Inc are:
Islam (Khalid)
Edward Jones
Greenlight Capital, Inc.
Islam (Khalid)
Edward Jones
Greenlight Capital, Inc.
How many institutions hold shares of Gain Therapeutics Inc (GANX)?
As of 2025Q4, 63 institutions hold shares of Gain Therapeutics Inc, with a combined market value of approximately 3.80M, accounting for 12.80% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.01%.
What is the biggest source of revenue for Gain Therapeutics Inc?
In --, the -- business generated the highest revenue for Gain Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
